Zuellig Pharma has acquired all rights, title, and interest in Cialis (tadalafil) from Eli Lilly in Singapore.
The transaction transfers the commercialization and distribution of the blockbuster erectile-dysfunction drug to the Dubai-based healthcare solutions provider, marking a strategic shift in how the brand is managed in the region.
The move allows Zuellig Pharma to deepen its portfolio of chronic-care and specialty medicines in Southeast Asia.
By taking direct control of the Cialis franchise, the distributor can better align supply chains and marketing efforts with local healthcare providers and pharmacies.
For Eli Lilly, the divestiture of the Singapore rights suggests a focus on reallocating resources toward higher-growth therapeutic areas or new market entries.
This development comes as Eli Lilly pursues significant expansion in other sectors.